OncoMatch/Clinical Trials/NCT06828354

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Is NCT06828354 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for ovarian cancer.

Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.NCT06828354Data as of May 2026

Treatment: SHR-A1811 · Paclitaxel · Doxorubicin Hydrochloride Liposome · Gemcitabine Hydrochloride for · Topotecan Hydrochloride for — This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify